(RTTNews) - Corvus Pharmaceuticals, Inc. (CRVS) announced positive results from Cohort 4 of its placebo-controlled Phase 1 clinical trial evaluating Soquelitinib, the company's lead ITK inhibitor, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results